Join us in accepting the LaCROSSe Out Cancer® Challenge!
Children with cancer are counting on us—and the need has never been greater. Pediatric cancer is still one of the leading causes of death by disease in children, yet it receives less than 4% of the federal cancer research budget—less than $3 per child. Nearly half of all pediatric cancer research depends on private support from organizations like the Pediatric Cancer Research Foundation (PCRF). Without bold action, lifesaving treatments, equitable access to care, and vital survivorship support remain out of reach for too many families.
To address this urgent need, PCRF has identified three core priorities: Powering Research, Equitable Care, and Survivorship & Mental Health.
Advancing the most promising science to deliver safer, more effective treatments.
Ensuring all children, regardless of background or geography, can access lifesaving therapies.
Providing support so kids and families can thrive long after treatment ends.
Driving these priorities forward is our bold Biomedical Lifecycle Model—a systemic strategy designed to addresses every stage of the pediatric cancer journey. This cradle-to-career-to-cure framework ensures children with cancer not only receive treatment today but benefit from a pipeline of solutions for tomorrow. This holistic model ensures that progress is not only possible, but lasting.
Your support fuels this momentum—bringing hope, discovery, and brighter futures for children and families impacted by cancer.
According to the Coalition Against Childhood Cancer, only approximately $220 Million goes to children’s research out of an annual $5 Billion cancer research budget.
Courageous Childhood Cancer Patients
Thatcher’s journey is a testament to resilience and joy. Despite battling Medulloblastoma since age two and enduring multiple surgeries, chemotherapy, and radiation, he has faced every challenge with incredible strength and continues to overcome the lasting effects of treatment.
Learn More »
Tae-León Butler was just nine years old when she was diagnosed with acute myeloid leukemia (AML). The active childhood she enjoyed as a Girl Scout was abruptly paused. In its place came tests, chemotherapy, procedures, and
Bill Thomas | October 22 Katie Taylor vividly remembers the first time she noticed her then two-year-old son, Clark, had developed a lazy eye. It was Friday afternoon on a holiday weekend and he’d just
By Bill Thomas | July 1st Federal funding for pediatric cancer grant research has never been in as precarious a position as it is right now. Over the last few months, we’ve seen provisions cut
By Bill Thomas | June 22nd When presenting their findings to a gathering of their peers, scientific researchers always hope for a positive response. That said, it’s hard to imagine a warmer reception than the
